Global Tumor Immunotherapy Market, By Type (Immunomodulatory Drugs Targeting Immune Cells, Other Immunomodulators, Oncolytic Virus, Cancer Vaccine, Adoptive Cellular Immunotherapy, Bispecific Antibody Targeting CD3), Technology (Monoclonal Antibodies, Cytokines and Immunomodulators, Vaccines, Checkpoint Inhibitors, Cell Therapies, Adoptive Cell Transfer, Others), Application (Blood Cancer, Liver Cancer, Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head and Neck Cancer, Ovarian Cancer, Others), End-User (Hospitals, Cancer Research Centers, Clinics, Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2028